Citi, acting through Citibank N.A., has been appointed by Stealth
BioTherapeutics Corp. (“Stealth”) as depositary bank for its
American Depositary Receipt (“ADR”) programme. Stealth’s ADRs trade on
the Nasdaq Global Market under the symbol “MITO.” Each ADR represents 12
ordinary shares of Stealth.
“We are pleased to have been selected by Stealth as depositary bank for
its Nasdaq listed ADR programme,” said Dirk Jones, Global Head of Issuer
Services, at Citi. “We look forward to supporting the expansion of
Stealth’s investor outreach through the expertise of our Investor
Relations Advisory team and the breadth of our global equity
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
Citi, the leading global bank, has approximately 200 million customer
accounts and does business in more than 160 countries and jurisdictions.
Citi provides consumers, corporations, governments and institutions with
a broad range of financial products and services, including consumer
banking and credit, corporate and investment banking, securities
brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com
| Twitter: @Citi | YouTube: www.youtube.com/citi
| Blog: http://blog.citigroup.com
| Facebook: www.facebook.com/citi
| LinkedIn: www.linkedin.com/company/citi
About Stealth BioTherapeutics
Stealth BioTherapeutics (“Stealth”) is a clinical-stage biotechnology
company focused on the discovery, development and commercialization of
novel therapies for diseases involving mitochondrial dysfunction.
Mitochondria, found in nearly every cell in the body, are the body’s
main source of energy production and are critical for normal organ
function. Dysfunctional mitochondria characterize a number of rare
genetic diseases, collectively known as primary mitochondrial diseases,
and are also involved in many common age-related diseases. Stealth
believes their lead product candidate, elamipretide, has the potential
to treat both rare genetic and common age-related mitochondrial
diseases. Stealth is studying elamipretide in the following primary
mitochondrial diseases: primary mitochondrial myopathy, Barth syndrome
and Leber’s hereditary optic neuropathy. The company is also studying
elamipretide in dry age-related macular degeneration. Stealth’s other
pipeline candidates include SBT-20, which is being evaluated for rare
peripheral neuropathies, and SBT-272, which is being evaluated for rare
neurodegenerative disease indications. The company has optimized its
discovery platform to identify novel mitochondrial-targeted compounds,
which may be nominated as therapeutic product candidates or utilized as
scaffolds to deliver other compounds to mitochondria. Stealth’s mission
is to be the leader in mitochondrial medicine, and the company has
assembled a highly experienced management team, board of directors and
group of scientific advisors to help them achieve this mission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005486/en/